Lupin launches Memantine Hydrochloride Extended-Release Capsules

In United States

Lupin announced the launch of its Memantine Hydrochloride Extended-Release Capsules, 7mg, 14mg, 21mg, 28mg having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Memantine Hydrochloride ER capsules 7mg, 14mg, 21mg, 28mg are the generic equivalents of Allergan's Namenda XR1' capsules. It is indicated for the treatment of moderate to severe dementia of the Alzheimer's type.

Memantine Hydrochloride ER capsules 7mg, 14mg, 21mg, 28mg had annual sales of approximately USD 936 million in the US (IQVIA MAT December 2017).

Powered by Capital Market - Live News


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)